1009539-28
Abbott Xience V RX Everolimus Eluting Coronary Stent System: 2.5mm x 28mm
$117.00
box of 1
Out of stock
Expiration:
Expired
Express: Need it tomorrow? Order in next 2 hours 8 minutes and choose overnight shipping at checkout.
We currently do not have this item in stock, but we can email you as soon as it is available!
The item listed above is expired and may be used for educational, training, and non-clinical research purposes only. Any product information appearing below, including the product indication statement, pertains to an in-date item only.
Gore-Tex 30" PT-9 tapercutting, double armed
$15.00 packets
Medtronic Biosyn undyed 18" CVF-21 taper
$65.50 box of 36
Medtronic Chromic Gut 30" GS-22 taper
$1.00 packets
Medtronic Maxon green 30" CV-23 taper
$229.00 box of 36
PDS II clear 18" PS-2 cutting
$7.90 packets
Medtronic Chromic Gut 30" GS-24 (CT) Taper
$149.00 box of 36
Gore-Tex 36" TH-26 taper, double armed
$10.00 packets
Description
XIENCE V
Everolimus Eluting Coronary Stent System
XIENCE V – a DES with superior outcomes that can take your performance to new heights. Abbott's XIENCE V is truly a next-generation DES, combining the proven deliverability of the MULTI-LINK VISION stent platform with a Multi-layer Coating Technology and everolimus to deliver superior outcomes for patients with coronary artery disease (CAD).
Additional information
| Size | 2.50mm |
|---|---|
| Arms | N/A |
| Manufacturer | |
| Stent Length | 28mm |
| Unit | box of 1 |
| Usable Length | 75cm |
- FDA Product Code: NIQ
- FDA Product Code Name: Coronary drug-eluting stent
- GMDN Term Code: 56284
- GMDN Term Name: Drug-eluting coronary artery stent, non-bioabsorbable-polymer-coated
- GMDN Term Description: A non-bioabsorbable metal tubular mesh structure covered with a non-bioabsorbable polymer and a drug coating that is designed to be implanted, via a delivery catheter, into a coronary artery (or saphenous vein graft) to maintain its patency typically in a patient with symptomatic atherosclerotic heart disease. The drug coating is slowly released and intended to inhibit restenosis by reducing vessel smooth muscle cell proliferation. Disposable devices associated with implantation may be included.
